Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein

Trevor S. Anderson,Amanda L. McCormick,Savanna L. Smith,Devin B. Lowe
DOI: https://doi.org/10.1186/s12915-024-01860-x
IF: 7.364
2024-03-16
BMC Biology
Abstract:Antibody drug conjugates (ADCs) constitute a promising class of targeted anti-tumor therapeutics that harness the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. ADC development is best suited to initially screening antibody candidates for desired properties that potentiate target cell cytotoxicity. However, validating and producing an optimally designed ADC requires expertise and resources not readily available to certain laboratories.
biology
What problem does this paper attempt to address?